|
JP2009526761A
(ja)
|
2006-01-30 |
2009-07-23 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環式チオフェン化合物および使用の方法
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
JP2010530901A
(ja)
*
|
2007-06-22 |
2010-09-16 |
ハイドラ バイオサイエンシズ インコーポレイテッド |
障害を治療するための方法および組成物
|
|
GB0722055D0
(en)
*
|
2007-11-09 |
2007-12-19 |
Argenta Discovery Ltd |
Compounds
|
|
BRPI0820171B8
(pt)
*
|
2007-11-16 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
|
|
CN101903378B
(zh)
*
|
2007-12-18 |
2014-03-12 |
埃科特莱茵药品有限公司 |
氨基三唑衍生物
|
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
MX2010008700A
(es)
|
2008-02-22 |
2010-08-30 |
Hoffmann La Roche |
Moduladores de beta-amiloide.
|
|
WO2009119088A1
(ja)
*
|
2008-03-25 |
2009-10-01 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
WO2009140517A1
(en)
|
2008-05-14 |
2009-11-19 |
Hydra Biosciences, Inc. |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2011036889A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2011036885A1
(ja)
*
|
2009-09-25 |
2011-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
BR112012024705A2
(pt)
*
|
2010-03-31 |
2016-06-07 |
Actelion Pharmaceuticals Ltd |
derivados antibacterianos de isoquinolin-3-ilureia
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
JP5889875B2
(ja)
*
|
2010-05-07 |
2016-03-22 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
アザインダゾール
|
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
CA2816753A1
(en)
|
2010-11-08 |
2012-05-18 |
Lycera Corporation |
N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
TW201307292A
(zh)
|
2010-12-17 |
2013-02-16 |
Hoffmann La Roche |
經取代之６，６－稠合含氮雜環化合物及其用途
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
CN103635472B
(zh)
|
2011-02-28 |
2018-01-12 |
阵列生物制药公司 |
丝氨酸/苏氨酸激酶抑制剂
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
CN103703000B
(zh)
|
2011-03-23 |
2015-11-25 |
安姆根有限公司 |
Cdk4/6和flt3的稠合三环双重抑制剂
|
|
AR088729A1
(es)
|
2011-03-29 |
2014-07-02 |
Actelion Pharmaceuticals Ltd |
Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
|
|
JP6097289B2
(ja)
*
|
2011-08-04 |
2017-03-15 |
アレイ バイオファーマ、インコーポレイテッド |
セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
|
|
ES2969977T3
(es)
|
2011-08-23 |
2024-05-23 |
Libertas Bio Inc |
Compuestos de pirimido-piridazinona y uso de los mismos
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
BR112014007788A2
(pt)
|
2011-10-03 |
2017-04-18 |
Univ North Carolina Chapel Hill |
compostos de pirrolopirimidina para tratamento do câncer
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
HUE053994T2
(hu)
|
2012-03-01 |
2021-08-30 |
Array Biopharma Inc |
Szerin/treonin kináz inhibitorok
|
|
MX361539B
(es)
|
2012-04-25 |
2018-12-10 |
Takeda Pharmaceuticals Co |
Compuesto heterociclico nitrogenado.
|
|
AU2013259737A1
(en)
|
2012-05-08 |
2014-10-02 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
JP6242868B2
(ja)
|
2012-05-08 |
2017-12-06 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
|
|
CN104302627A
(zh)
|
2012-05-22 |
2015-01-21 |
北卡罗来纳大学教堂山分校 |
用于治疗癌症的嘧啶化合物
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
EP2873669A4
(en)
|
2012-07-13 |
2015-11-25 |
Takeda Pharmaceutical |
HETEROCYCLIC CONNECTION
|
|
MX363388B
(es)
*
|
2012-07-27 |
2019-03-20 |
Biogen Ma Inc |
Agentes moduladores de autotaxina.
|
|
ES2618004T3
(es)
*
|
2012-08-07 |
2017-06-20 |
Merck Patent Gmbh |
Derivados de piridopirimidina como inhibidores de proteínas quinasas
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014028479A1
(en)
|
2012-08-13 |
2014-02-20 |
Envoy Therapeutics, Inc. |
Quinoxaline derivatives as gpr6 modulators
|
|
AR092253A1
(es)
|
2012-08-27 |
2015-04-08 |
Array Biopharma Inc |
Inhibidores de serina/treonina cinasa
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
EP2897947B1
(en)
|
2012-09-21 |
2016-10-26 |
Bristol-Myers Squibb Company |
Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
|
|
EP2897954B1
(en)
|
2012-09-21 |
2016-10-26 |
Bristol-Myers Squibb Company |
Fluoroalkyl-1,4-benzodiazepinone compounds
|
|
WO2014044846A1
(en)
|
2012-09-24 |
2014-03-27 |
Evotec (Uk) Ltd. |
3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
|
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
WO2014060381A1
(de)
*
|
2012-10-18 |
2014-04-24 |
Bayer Cropscience Ag |
Heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
US9771330B2
(en)
|
2012-11-27 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
JP6669499B2
(ja)
|
2013-02-15 |
2020-03-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物
|
|
JP2016510000A
(ja)
|
2013-02-20 |
2016-04-04 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物およびその使用
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
EP2975031A4
(en)
|
2013-03-14 |
2017-04-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
CN104098563A
(zh)
*
|
2013-04-02 |
2014-10-15 |
山东亨利医药科技有限责任公司 |
Jnk抑制剂化合物
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
ES2950424T3
(es)
|
2013-07-03 |
2023-10-09 |
Takeda Pharmaceuticals Co |
Compuesto de amida
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
JP6427491B2
(ja)
|
2013-07-03 |
2018-11-21 |
武田薬品工業株式会社 |
複素環化合物
|
|
JPWO2015012328A1
(ja)
|
2013-07-24 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
KR102529049B1
(ko)
|
2013-08-14 |
2023-05-08 |
노파르티스 아게 |
암의 치료를 위한 조합 요법
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
NZ719185A
(en)
|
2013-11-01 |
2017-11-24 |
Kala Pharmaceuticals Inc |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3078660B1
(en)
*
|
2013-12-06 |
2022-07-13 |
MycHunter Therapeutics, Inc. |
Novel quinazoline derivative
|
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
|
WO2015095795A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
JO3466B1
(ar)
|
2013-12-20 |
2020-07-05 |
Takeda Pharmaceuticals Co |
مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
|
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
|
KR20160106622A
(ko)
|
2014-01-29 |
2016-09-12 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
화합물
|
|
ES2717757T3
(es)
|
2014-01-29 |
2019-06-25 |
Glaxosmithkline Ip Dev Ltd |
Compuestos
|
|
JP6526034B2
(ja)
|
2014-02-14 |
2019-06-05 |
武田薬品工業株式会社 |
Ｇｐｒ６のピリドピラジンモジュレーター
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
JP6752715B2
(ja)
|
2014-03-26 |
2020-09-09 |
アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
組合せ
|
|
MX373150B
(es)
|
2014-03-26 |
2020-04-21 |
Astex Therapeutics Ltd |
Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
US20150291606A1
(en)
|
2014-04-11 |
2015-10-15 |
The University Of North Carolina At Chapel Hill |
Mertk-specific pyrrolopyrimidine compounds
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
US9758518B2
(en)
|
2015-03-04 |
2017-09-12 |
Pimera, Inc. |
Compositions, uses and methods for making them
|
|
PL3140305T3
(pl)
|
2014-05-09 |
2018-10-31 |
Pimera, Inc. |
Nowe kompozycje, ich zastosowania i sposoby wytwarzania
|
|
KR20170032244A
(ko)
|
2014-07-26 |
2017-03-22 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
ES2735087T3
(es)
|
2014-12-24 |
2019-12-16 |
Gilead Sciences Inc |
Compuestos de pirimidina fusionados para el tratamiento de VIH
|
|
BR112017013440A2
(pt)
|
2014-12-24 |
2018-01-09 |
Gilead Sciences, Inc. |
compostos de isoquinolina para o tratamento de hiv
|
|
TWI699355B
(zh)
|
2014-12-24 |
2020-07-21 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
|
TWI719960B
(zh)
|
2015-02-10 |
2021-03-01 |
英商阿斯迪克治療公司 |
新穎組成物
|
|
EP3256450B1
(en)
|
2015-02-11 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
|
DK3353177T3
(da)
|
2015-09-23 |
2020-08-24 |
Janssen Pharmaceutica Nv |
Tricykliske heterocykler til behandling af cancer
|
|
AU2016328693B2
(en)
|
2015-09-23 |
2021-03-11 |
Janssen Pharmaceutica Nv |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
AU2016344118A1
(en)
|
2015-10-27 |
2018-05-10 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
WO2017075178A1
(en)
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
RU2018117503A
(ru)
|
2015-10-27 |
2019-11-28 |
Мерк Шарп И Доум Корп. |
ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
|
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
AR108326A1
(es)
*
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
AR108325A1
(es)
*
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
|
MA45122A
(fr)
*
|
2016-05-24 |
2019-04-10 |
Constellation Pharmaceuticals Inc |
Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
|
|
EP3463355B1
(en)
*
|
2016-05-26 |
2024-08-28 |
Sonic Master Limited |
Modulators of dux4 for regulation of muscle function
|
|
CN109563095B
(zh)
*
|
2016-06-02 |
2021-10-29 |
细胞基因公司 |
动物和人抗疟剂
|
|
WO2018029336A1
(en)
|
2016-08-12 |
2018-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
|
|
TW201811795A
(zh)
|
2016-08-24 |
2018-04-01 |
美商亞闊股份有限公司 |
胺基－吡咯并嘧啶酮化合物及其用途
|
|
AU2017324713B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
KR20190051010A
(ko)
|
2016-09-08 |
2019-05-14 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정형 및 그의 용도
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
CA3057741A1
(en)
|
2017-03-28 |
2018-10-04 |
Pimera, Inc. |
Novel crystal forms of a pol1 inhibitor
|
|
RU2019133646A
(ru)
|
2017-03-30 |
2021-04-30 |
Ф. Хоффманн-Ля Рош Аг |
Изохинолины в качестве ингибиторов hpk1
|
|
KR20190140011A
(ko)
|
2017-04-28 |
2019-12-18 |
아사나 바이오사이언시스 엘엘씨 |
아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
US10604514B2
(en)
*
|
2017-10-19 |
2020-03-31 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
US10653688B2
(en)
|
2017-10-27 |
2020-05-19 |
Samumed, Llc |
6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
|
US10413537B2
(en)
|
2017-10-27 |
2019-09-17 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
|
US10703748B2
(en)
|
2017-10-31 |
2020-07-07 |
Samumed, Llc |
Diazanaphthalen-3-yl carboxamides and preparation and use thereof
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
CN112601584A
(zh)
*
|
2018-07-24 |
2021-04-02 |
豪夫迈·罗氏有限公司 |
异喹啉化合物及其用途
|
|
TW202024053A
(zh)
*
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
US12187721B2
(en)
|
2018-10-17 |
2025-01-07 |
Array Biopharma Inc. |
Protein tyrosine phosphatase inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021004547A1
(en)
*
|
2019-07-11 |
2021-01-14 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of hpk1
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
SMT202500271T1
(it)
|
2020-07-02 |
2025-09-12 |
Incyte Corp |
Composti di urea triciclici come inibitori di v617f di jak2
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
AU2021358123A1
(en)
|
2020-10-05 |
2023-06-08 |
Enliven Inc. |
5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
|
|
CN114380752A
(zh)
*
|
2020-10-22 |
2022-04-22 |
南开大学 |
一种制备n-取代-2，4-喹唑啉二酮类化合物的合成方法
|
|
WO2022140231A1
(en)
|
2020-12-21 |
2022-06-30 |
Incyte Corporation |
Deazaguaine compounds as jak2 v617f inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115583946B
(zh)
*
|
2021-07-06 |
2026-01-16 |
赛诺哈勃药业（成都）有限公司 |
杂环化合物及其作为cdk抑制剂的用途
|
|
KR20240083168A
(ko)
|
2021-07-14 |
2024-06-11 |
블루프린트 메디신즈 코포레이션 |
Map4k1 저해제로서의 헤테로사이클 화합물
|
|
FI4426434T3
(fi)
|
2021-11-02 |
2025-11-24 |
Flare Therapeutics Inc |
Pparg:n käänteisagonisteja ja niiden käyttöjä
|
|
WO2023126951A1
(en)
|
2022-01-03 |
2023-07-06 |
Yeda Research And Development Co. Ltd. |
Inhibitors of autophagy-related protein-protein interactions
|
|
CN119173514A
(zh)
|
2022-03-17 |
2024-12-20 |
因赛特公司 |
作为jak2 v617f抑制剂的三环脲化合物
|
|
CN116731030B
(zh)
*
|
2023-06-07 |
2026-03-31 |
湖北医药学院 |
几种呋喃并嘧啶-布洛芬杂合衍生物的合成方法及抗肿瘤的应用
|
|
AU2024290917A1
(en)
*
|
2023-07-03 |
2026-01-22 |
Cervero Therapeutics, LLC |
Polo-like kinase 1 inhibitors
|